Use of Sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience

References

• Centers for Disease Control and Prevention (CDC). Science brief: evidence used to update the list of underlying medical conditions associated with higher risk for severe COVID-19 .,» 2021. [Online]. Available:https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html. Accessed 16 June 2022.
   Google Scholar
• Vimercati A, De Nola R, Trerotoli P, et al. COVID-19 infection in pregnancy: obstetrical risk factors and neonatal outcomes-A monocentric, single-cohort study. Vaccines (Basel). 2022 Jan 21;10(2):166. DOI:10.3390/vaccines10020166.
   PubMed Web of Science ®Google Scholar
• Kareva I. Immune suppression in pregnancy and cancer: parallels and insights. Transl Oncol. 2020 Jul;13(7):100759. DOI:10.1016/j.tranon.2020.100759.
   PubMed Web of Science ®Google Scholar
• Epelboin S, Labrosse J, De Mouzon J, et al. Obstetrical outcomes and maternal morbidities associated with COVID-19 in pregnant women in France: a national retrospective cohort study. PLOS Med. 2021 Nov 30;18(11):e1003857. DOI:10.1371/journal.pmed.1003857.
   PubMed Web of Science ®Google Scholar
• Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320. DOI:10.1136/bmj.m3320.
   PubMedGoogle Scholar
• Nana M, Nelson-Piercy C. COVID-19 in pregnancy. Clin Med (Lond). 2021 Sep;21(5):e446–450. DOI:10.7861/clinmed.2021-0503.
   PubMed Web of Science ®Google Scholar
• Resta L, Vimercati A, Cazzato G, et al. SARS-CoV-2 and placenta: new insights and perspectives. Viruses. 2021 Apr 21;13(5):723.
   PubMed Web of Science ®Google Scholar
• Rebutini PZ, Zanchettin AC, Stonoga ETS, et al. Association between COVID-19 pregnant women symptoms severity and placental morphologic features. Front Immunol. 2021 May 26;12:685919. DOI:10.3389/fimmu.2021.685919.
   PubMed Web of Science ®Google Scholar
• Italian Medicine Agenacy (AIFA). Medicines usable for treatment of COVID-19 diseaseAvailable at https://www.aifa.gov.it/en/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19
   Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941–1950. DOI:10.1056/NEJMoa2107934.
   PubMed Web of Science ®Google Scholar
• Folkman R, Blennow O, Tovatt T, et al. Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy. Infection. 2022 Apr 28;51(1):1–3.
   PubMed Web of Science ®Google Scholar
• Gupta I, Arguello Perez ES. Use of Sotrovimab in a pregnant patient with COVID-19infection. Cureus. 2022 Feb 27;14(2):e22658.
   PubMed Web of Science ®Google Scholar
• Ya H. Sotrovimab: first Approval. Drugs. 2022 Mar;82(4):477–484. DOI:10.1007/s40265-022-01690-7.
   PubMed Web of Science ®Google Scholar
• Di Gennaro F, Petrosillo N. New endemic and pandemic pathologies with interhuman airborne transmission through ear, nose and throat anatomical sites. Acta Otorhinolaryngol Ital. 2022 Apr;42(Suppl. 1):S5–13. DOI:10.14639/0392-100X-suppl.1-42-2022-01.
   PubMedGoogle Scholar
• European Medicine Agency (EMA). EMA receives application for marketing authorisation for Xevudy (sotrovimab) for treating patients with COVID-19. Available at https://www.ema.europa.eu/en/news/ema-receives-application-marketing-authorisation-xevudy-sotrovimab-treating-patients-covid-19
   Google Scholar
• Celewicz A, Celewicz M, Michalczyk M, et al. Pregnancy as a risk factor of severe COVID-19. J Clin Med. 2021 Nov 22;10(22):5458. DOI:10.3390/jcm10225458.
   PubMed Web of Science ®Google Scholar
• Galang RR, Newton SM, Woodworth KR, et al. Risk factors for illness severity among pregnant women with confirmed severe acute respiratory syndrome coronavirus 2 infection-surveillance for emerging threats to mothers and babies network, 22 state, local, and territorial health departments, 29 March 2020-5 March 2021. Clin Infect Dis. 2021 Jul 15;73(Suppl 1):S17–23. DOI:10.1093/cid/ciab432.
   PubMedGoogle Scholar
• Rad HS, Röhl J, Stylianou N, et al. The effects of COVID-19 on the placenta during pregnancy. Front Immunol. 2021 Sep 15;12:743022.10.3389/fimmu.2021.743022.
   PubMed Web of Science ®Google Scholar
• Koehler J, Ritzer B, Weidlich S, et al. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. Infection. 2021 Dec;49(6):1313–1318.
   PubMed Web of Science ®Google Scholar
• Resta L, Vimercati A, Cazzato G, et al. SARS-CoV-2, placental histopathology, gravity of infection and immunopathology: is there an association? Viruses. 2022 Jun 18;14(6):1330.
   PubMed Web of Science ®Google Scholar
• Saitoh A, Takaku M, Saitoh A. High rates of vaccine hesitancy among pregnant women during the coronavirus disease 2019 (COVID-19) pandemic in Japan. Hum Vaccin Immunother. 2022 Apr 27;18(5):1–7.
   Web of Science ®Google Scholar
• Iacobucci G. Covid-19 and pregnancy: vaccine hesitancy and how to overcome it. BMJ. 2021 Nov 22;375(2862). DOI:10.1136/bmj.n2862 PMID: 34810161.
   Google Scholar
• Shook LL, Kishkovich TP, Edlow AG. Countering COVID-19 vaccine hesitancy in pregnancy: the “4 Cs”. Am J Perinatol. 2021 Oct 19;39(10):1048–1054.
   PubMed Web of Science ®Google Scholar
• Italian National Istitute of Health (ISS). IRIDA (integrated rapid infectious disease analysis) ARIES (advanced research infrastructure for experimentation in GenomicS). Available at https://irida.iss.it/irida21-aries/login
   Google Scholar
• Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022 Jun 17;608(7923):593–602. DOI:10.1038/s41586-022-04980-y
   PubMed Web of Science ®Google Scholar
• Wilhelm A, Widera M, Grikscheit K, et al. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. EBioMedicine. 2022 Jul 11;82:104158. DOI:10.1016/j.ebiom.2022.104158.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022 Feb 3;185(3):447–456.e11. DOI:10.1016/j.cell.2021.12.032.
   PubMed Web of Science ®Google Scholar